MedCity News June 21, 2024
Frank Vinluan

FDA reviewers concluded the data for Sarepta Therapeutics’ Elevidys were insufficient to show efficacy in the rare muscle disorder Duchenne muscular dystrophy. Peter Marks, the agency’s top biologics official, reviewed the same data and reached a different conclusion.

A Sarepta Therapeutics gene therapy that failed its confirmatory test has now converted its accelerated FDA approval into a traditional one, expanding use of the treatment to a wider group of Duchenne muscular dystrophy patients. In approving the therapy, the FDA’s top biologics official cited a wider range of supporting evidence, overruling agency staff who were unconvinced that the data show the therapy works to treat the muscle-wasting disease.

The FDA decision announced late Thursday permits use of the therapy, Elevidys, in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
FDA Clears Emerging Brain PET System
STAT+: Applesauce lead contamination could not have been prevented, top FDA official suggests
Trump’s FDA commissioner on regulating AI
FDA creates communication ‘super office’ at CDRH

Share This Article